echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > Reduce cell manufacturing time and increase cell yield! TG Medical completes the important layout of the cell manufacturing process!

    Reduce cell manufacturing time and increase cell yield! TG Medical completes the important layout of the cell manufacturing process!

    • Last Update: 2021-02-09
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    January 21, Thermo Genesis Corp., a U.S.-owned subsidiary of Boya Holdings, announced the completion of the construction and certification of GMP Clean Shop in California, USA, for the production of consumables for all X-Series™s range of cell processing technology platforms.
    production of cell therapy products must meet GMP standards. GMP standard is a set of quality management standards applicable to the pharmaceutical industry, through the plant to the ground, from equipment to production, sanitary conditions, as well as air, water purification, personnel quality and training requirements, production and documentation specifications and many other details of the strict requirements, to ensure that products in high-specification quality standards to maintain continuous production, and the production process of non-conformity risk to minimize the standard management system. Boao's new GMP cleansing workshop in California, USA, strengthens Boya Holdings' cell manufacturing supply chain and is an important layout for TG Healthcare to provide the industry with GMP-compliant cell manufacturing processes. The
    X-Series™ series is part of TG Medical's self-developed portfolio, which includes automated, closed cell manufacturing processes such as cell separation, purification, washing and preparation to meet the different needs of cell therapy research and development stages as well as large-scale commercial production stages.
    this series of products has the potential to reform cell manufacturing, to achieve the optimization of multiple links in cell manufacturing, greatly shorten the time of cell manufacturing, improve cell production, help the industry to solve the current bottlenecks in cell manufacturing.
    Currently, TG Medical's line-up of X-Series™ includes PXP®, an automated single nuclear cell separation system X-LAB®, a closed cell cleaning and preparation system X-WASH®, and an X-Mini ™ for efficient cell selection in portable laboratories for instant systems in the operating room.
    , other products in this range will also be available, including kit X-Auto™ for clinical users in large central laboratories and non-commercial production phases, and X-Clini ™ for large-scale commercial production of GMP.
    Since its launch in May 2018, the X-Series ™ series has received a lot of attention from the market, and TG Medical President Zhu Haihong said, "We have completed the assembly of supplies, automatic control modules and data interfaces for this range of products, so that we can better control the supply chain and provide customers with higher quality products and better service." At the same time, TG Medical is well-equipped to significantly increase production rates to keep up with the growing ™ X-Series products. "
    currently, there have been a number of cell therapy products in the United States, the European Union, Canada, Australia, Japan and other regions have been approved for market, some domestic cell therapy projects have been opened to clinical applications and set pricing standards. With the gradual liberalization of global cell therapy, the industry's demand for automated and standardized large-scale cell manufacturing is becoming more and more significant. From the development of automated cell manufacturing technology platforms to the strengthening of the supply chain, Boya's TG Medical continues to contribute to the standardization of large-scale cell manufacturing to meet the growing market demand and ultimately improve access to cell therapy for the benefit of more patients. (Bio Valley)
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.